Randomized Clinical Trial to Evaluate the Predictive Accuracy of a Gene Expression for Stage I-II Breast Cancer
NCT00336791
Completed
Primary Objectives: 1. To prospectively evaluate the predictive accuracy of a previously discovered gene expression profile-based test to foretell pathologic complete response (pCR) to preoperative paclitaxel/FAC (5-fluorouracil, doxorubicin, cyclophosphamide) chemotherapy for stage I-III breast cancer. 2. To evaluate if our genomic predictive test is specific to the paclitaxel/FAC regimen or it also predicts increased sensitivity to FAC only chemotherapy. Secondary Objectives: 1. To discover... Read More
Gender:
ALL
Ages:
All
Trial Updated:
02/13/2012
Locations: UT MD Anderson Cancer Center, Houston, Texas +3 locations
Conditions: Breast Cancer
Register for Updates
Capecitabine, Paclitaxel, and Trastuzumab in Treating Patients With Metastatic Breast Cancer
NCT00006108
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining chemotherapy with monoclonal antibody therapy may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of combining capecitabine, paclitaxel, and trastuzumab in treating patients who hav... Read More
Gender:
ALL
Ages:
Between 18 years and 59 years
Trial Updated:
02/03/2012
Locations: Lineberger Comprehensive Cancer Center, UNC, Chapel Hill, North Carolina
Conditions: Breast Cancer
Register for Updates
Pilot Study of 18F Fluoropaclitaxel (FPAC)
NCT00572598
Completed
Multidrug resistance (MDR) is a cause of treatment failure in many cancer patients. MDR refers to a phenotype whereby a tumor is resistant to a large number of natural chemotherapeutic drugs. Having prior knowledge of the presence of such resistance would decrease morbidity from unsuccessful therapy and allow for the selection of individuals who may benefit from co-administration of MDR inhibiting drugs. The Tc-99m labeled single photon emitting radiotracers sestamibi and tetrofosmin have shown... Read More
Gender:
ALL
Ages:
Between 18 years and 90 years
Trial Updated:
01/11/2012
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Breast Cancer
Register for Updates
Safety and Efficacy of the ZoMaxx™ Drug-Eluting Stent System in Coronary Arteries
NCT00140101
Completed
The purpose of this study is to demonstrate the safety and efficacy of the ZoMaxx drug-eluting stent in patients with blockage of native coronary arteries. The study is designed to demonstrate non-inferiority to the TAXUS Express2 Paclitaxel-Eluting Stent that has proven superior to bare metal stents and is a recognized standard of care.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/06/2012
Locations: Huntsville Hospital, Huntsville, Alabama +91 locations
Conditions: Coronary Disease, Coronary Artery Disease, Coronary Restenosis
Register for Updates
Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
NCT00111904
Completed
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel works in treating patients with unresectable locally advanced or metastatic pancreatic cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2011
Locations: Florida Cancer Specialists - Bonita Springs, Bonita Springs, Florida +4 locations
Conditions: Pancreatic Cancer
Register for Updates
SPIRIT III Clinical Trial of the XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
NCT00180479
Completed
This study is divided into 5 arms: 1. Randomized Clinical Trial (RCT): Prospective, randomized, active-controlled, single blind, parallel two-arm multi-center clinical trial in the United States (US) comparing XIENCE V® Everolimus Eluting Coronary Stent System (CSS) (2.5, 3.0, 3.5 mm diameter stents) to the Food and Drug Administration (FDA) approved commercially available active control TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent (TAXUS® EXPRESS2™ PECS) System 2. US 2.25 mm non-randomiz... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/16/2011
Locations: Baptist Medical Center Princeton, Birmingham, Alabama +64 locations
Conditions: Stents, Coronary Artery Disease, Total Coronary Occlusion, Coronary Artery Restenosis, Stent Thrombosis, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
Register for Updates
Abraxane and Temodar Plus Genasense in Advanced Melanoma
NCT00409383
Unknown
This study is designed to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of combination treatment with Temodar®, Genasense®, and Abraxane® in chemotherapy-naïve subjects with advanced melanoma and normal lactate dehydrogenase (LDH).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2011
Locations: New York University Cancer Center, New York, New York
Conditions: Melanoma
Register for Updates
Safety and Effectiveness of Combretastatin A-4 Phosphate Combined With Chemotherapy in Advanced Solid Tumors
NCT00113438
Completed
This is a study evaluating the safety and effectiveness of Combretastatin A4 Phosphate (CA4P) combined with the chemotherapy drugs, carboplatin and paclitaxel. The full treatment and observation time should be about 5 months. During this time the patient should receive 18 CA4P infusions and 6 carboplatin followed by paclitaxel treatments. Patients will be randomized into one of two CA4P dose-level groups in order to recommend a preferred dose-level for future studies. At least 2 dynamic contrast... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2011
Locations: Huntsman Cancer Institute, Salt Lake City, Utah
Conditions: Cancer, Tumor
Register for Updates
Combination Chemotherapy for Patients With Brain Cancer
NCT00002814
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy using paclitaxel and topotecan, plus G-CSF, in treating patients with glioblastoma multiforme or anaplastic astrocytoma that is refractory or recurrent.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/26/2011
Locations: Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire
Conditions: Brain and Central Nervous System Tumors
Register for Updates
Safety and Efficacy of Angiotech Vascular Wrap Paclitaxel-Eluting Mesh for Hemodialysis Vascular Access
NCT00448708
Terminated
This is a multi-center clinical study in subjects requiring arteriovenous grafts in the upper extremity for hemodialysis access. All subjects will provide informed consent before undergoing any study procedures. The study will consist of multiple subject visits and telephone contacts during the 52 week study period. During the study period subjects must also maintain an appropriate hemodialysis schedule. IDE Number: G060250
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/13/2011
Locations: Clinical Research Center, Birmingham, Alabama +32 locations
Conditions: Kidney Diseases, ESRD
Register for Updates
Abraxane Plus Carboplatin for Recurrent Platinum-Sensitive Ovarian Cancer
NCT00466986
Completed
The purpose of this study is to determine if the combination of Abraxane and Carboplatin together will improve the chances of controlling recurrent ovarian/fallopian tube/peritoneal cancer.
Gender:
FEMALE
Ages:
All
Trial Updated:
10/07/2011
Locations: Southeastern Gynecologic Oncology, Atlanta, Georgia
Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Register for Updates
A Phase III Randomized Trial Assessing the Utility of a Test Dose Program With Taxanes
NCT00277043
Completed
The purpose of this study are to determine whether a test dose program for taxanes will reduce the rate and/or severity of hypersensitivity reactions (HSR); and to determine whether a test dose program for taxanes will result in cost reduction due to decreased drug wastage.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/23/2011
Locations: University of New Mexico, Albuquerque, New Mexico
Conditions: Supportive, Ill-defined Sites
Register for Updates